STOCK TITAN

Praxis Precision Medicines (PRAX) director receives RSU and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Praxis Precision Medicines director Stuart A. Arbuckle reported equity compensation awards. He received 1,371 restricted stock units, each representing a contingent right to one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting. He was also granted options to purchase 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments beginning July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. After these awards, he directly holds 2,537 common shares and 648 stock options, reflecting routine director compensation rather than open-market buying.

Positive

  • None.

Negative

  • None.
Insider Arbuckle Stuart A
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 648 $0.00 --
Grant/Award Common Stock 1,371 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 648 shares (Direct, null); Common Stock — 2,537 shares (Direct, null)
Footnotes (1)
  1. Mr. Arbuckle was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
RSU grant 1,371 units Restricted stock units awarded to director on June 10, 2026
Shares after award 2,537 shares Common stock directly held after RSU grant
Option grant size 648 options Stock options granted on June 10, 2026
Option exercise price $240.66 per share Conversion or exercise price for 648 options
Option expiration June 10, 2036 Expiration date of stock option grant
RSU vesting date June 10, 2027 or 2027 meeting Single-installment vesting trigger for 1,371 RSUs
Option vesting start July 10, 2026 First of twelve monthly vesting installments for options
restricted stock units financial
"Mr. Arbuckle was awarded 1,371 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share."
stock option financial
"The shares subject to this option shall vest in twelve (12) equal monthly installments."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "240.6600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Arbuckle Stuart A

(Last)(First)(Middle)
C/O PRAXIS PRECISION MEDICINES, INC.
99 HIGH STREET, 30TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A(1)1,371A$02,537D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$240.6606/10/2026A648 (2)06/10/2036Common Stock648$0648D
Explanation of Responses:
1. Mr. Arbuckle was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Remarks:
/s/ Alex Nemiroff, as Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Praxis Precision Medicines (PRAX) report for Stuart Arbuckle?

Praxis Precision Medicines reported that director Stuart A. Arbuckle received 1,371 restricted stock units and stock options for 648 shares as equity compensation, rather than making any open-market share purchases or sales.

How many Praxis Precision Medicines shares does Stuart Arbuckle hold after this Form 4?

Following the reported equity awards, Stuart A. Arbuckle directly holds 2,537 shares of Praxis Precision Medicines common stock, plus stock options covering an additional 648 shares granted under the company’s compensation arrangements.

What are the vesting terms of Stuart Arbuckle’s 1,371 Praxis restricted stock units?

The 1,371 restricted stock units vest in a single annual installment on the earlier of June 10, 2027 or the date of Praxis Precision Medicines’ 2027 annual meeting of stockholders, and are settled only in shares of common stock.

What are the key terms of Stuart Arbuckle’s Praxis stock option grant?

Stuart Arbuckle received options for 648 shares of Praxis common stock at a $240.66 exercise price, vesting in twelve equal monthly installments from July 10, 2026 through the earlier of June 10, 2027 or the 2027 annual meeting, expiring June 10, 2036.

Does this Praxis (PRAX) Form 4 show insider buying or selling in the market?

The Form 4 shows equity compensation grants, not market trades. Stuart Arbuckle acquired restricted stock units and stock options at no cash cost, with no open-market share purchases or sales reported in this filing.